Ani Pharmaceuticals (ANIP) EBIAT: 2009-2025
Historic EBIAT for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $26.6 million.
- Ani Pharmaceuticals' EBIAT rose 210.14% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 672.15%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
- As of Q3 2025, Ani Pharmaceuticals' EBIAT stood at $26.6 million, which was up 211.35% from $8.5 million recorded in Q2 2025.
- Ani Pharmaceuticals' EBIAT's 5-year high stood at $26.6 million during Q3 2025, with a 5-year trough of -$24.2 million in Q3 2024.
- Over the past 3 years, Ani Pharmaceuticals' median EBIAT value was $6.2 million (recorded in 2023), while the average stood at $4.6 million.
- As far as peak fluctuations go, Ani Pharmaceuticals' EBIAT tumbled by 23,506.98% in 2022, and later skyrocketed by 1,165.25% in 2024.
- Quarterly analysis of 5 years shows Ani Pharmaceuticals' EBIAT stood at -$24.1 million in 2021, then soared by 82.42% to -$4.2 million in 2022, then spiked by 127.22% to $1.2 million in 2023, then slumped by 989.70% to -$10.3 million in 2024, then surged by 210.14% to $26.6 million in 2025.
- Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.